➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Johnson and Johnson
Baxter
Dow
Boehringer Ingelheim

Last Updated: September 17, 2021

DrugPatentWatch Database Preview

Details for Patent: 7,084,245


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,084,245
Title:Peptides that bind to the erythropoietin receptor
Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
Inventor(s): Holmes; Christopher P. (Saratoga, CA), Yin; Qun (Palo Alto, CA), Lalonde; Guy (Woodside, CA), Schatz; Peter J. (Cupertino, CA), Tumelty; David (Sunnyvale, CA), Palani; Balu (Cupertino, CA), Zemede; Genet (Santa Clara, CA)
Assignee: Affymax, Inc. (Palo Alto, CA)
Application Number:10/844,968
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Drugs Protected by US Patent 7,084,245

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Takeda Pharms Usa OMONTYS peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-007 Mar 27, 2012 DISCN No No ⤷  Try it Free ⤷  Try it Free Y Y TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE ⤷  Try it Free
Takeda Pharms Usa OMONTYS peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-008 Mar 27, 2012 DISCN No No ⤷  Try it Free ⤷  Try it Free Y Y TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE ⤷  Try it Free
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-001 Mar 27, 2012 DISCN No No ⤷  Try it Free ⤷  Try it Free Y Y TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE ⤷  Try it Free
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-002 Mar 27, 2012 DISCN No No ⤷  Try it Free ⤷  Try it Free Y Y TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE ⤷  Try it Free
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-003 Mar 27, 2012 DISCN No No ⤷  Try it Free ⤷  Try it Free Y Y TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,084,245

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 2042 ⤷  Try it Free
Austria 428727 ⤷  Try it Free
Australia 2004238870 ⤷  Try it Free
Brazil PI0411155 ⤷  Try it Free
Canada 2525568 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Colorcon
McKinsey
AstraZeneca
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.